These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13397175)

  • 1. Dissolving blood clots.
    GLENN WW; HUME M
    Conn State Med J; 1957 Feb; 21(2):118-22. PubMed ID: 13397175
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of proteolytic enzymes for prevention of postoperative adhesions in the abdominal cavity].
    Zhenchevskiĭ RA
    Vestn Khir Im I I Grek; 1972 Oct; 109(10):48-53. PubMed ID: 4268101
    [No Abstract]   [Full Text] [Related]  

  • 3. [Medical therapy and surgical therapy of radiodermatitis].
    Mela V; Raso S
    Minerva Med; 1966 Jul; 57(57):2582-8. PubMed ID: 4223235
    [No Abstract]   [Full Text] [Related]  

  • 4. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study on plant latex proteases and their involvement in hemostasis: a special emphasis on clot inducing and dissolving properties.
    Rajesh R; Shivaprasad HV; Gowda CD; Nataraju A; Dhananjaya BL; Vishwanath BS
    Planta Med; 2007 Aug; 73(10):1061-7. PubMed ID: 17691056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endopleural fibrin bodies].
    D'AGOSTINO F; BIONDO G
    Minerva Med; 1957 Aug; 48(69):2742-6. PubMed ID: 13483277
    [No Abstract]   [Full Text] [Related]  

  • 7. FIBRINOLYSIN for treatment of blood-clots in man.
    Lancet; 1958 Sep; 2(7047):624-5. PubMed ID: 13588952
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
    Landskroner K; Olson N; Jesmok G
    J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot.
    Bagoly Z; Haramura G; Muszbek L
    Thromb Haemost; 2007 Aug; 98(2):359-67. PubMed ID: 17721618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on a proteolytic enzyme system of the blood. I. Inhibition of fibrinolysin.
    LEWIS JH; FERGUSON JH
    J Clin Invest; 1950 Apr; 29(4):486-90. PubMed ID: 15415452
    [No Abstract]   [Full Text] [Related]  

  • 12. [Changes induced by a heparin-like sulfo-polysaccharide on the antitryptic, antifibrinolytic and antielastolytic activity of human blood].
    COCCHERI S; PRETOLANI E; GENNARI P
    Boll Soc Ital Biol Sper; 1963 Feb; 39():184-8. PubMed ID: 14021858
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel.
    Buchta C; Hedrich HC; Macher M; Höcker P; Redl H
    Biomaterials; 2005 Nov; 26(31):6233-41. PubMed ID: 15921738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activation of a proteolytic enzyme in blood by animal tissue.
    ASTRUP T
    Biochem J; 1951 Nov; 50(1):5-11. PubMed ID: 14904365
    [No Abstract]   [Full Text] [Related]  

  • 15. Human U937 monocyte behavior and protein expression on various formulations of three-dimensional fibrin clots.
    Mana M; Cole M; Cox S; Tawil B
    Wound Repair Regen; 2006; 14(1):72-80. PubMed ID: 16476075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood clotting activities of thrombolytic agents with special reference to a Hageman-like effect.
    IATRIDIS SG; WILSON EG; FERGUSON JH; RIERSON HA
    Thromb Diath Haemorrh; 1960 Oct; 5():50-60. PubMed ID: 13717314
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrin clot structure in patients with end-stage renal disease.
    Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
    Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on dynamics of fibrin and of fibronolytic ferment in tissue culture].
    HOWORKA E
    Med Dosw Mikrobiol; 1954; 6(3):265-9. PubMed ID: 13213605
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the fibrinolytic and fibrinogenolytic effects of plasminogen activators and proteolytic enzymes in plasma.
    SAWYER WD; ALKJAERSIG N; FLECTCHER AP; SHERRY S
    Thromb Diath Haemorrh; 1960 Dec; 5():149-61. PubMed ID: 13746960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.